

A Stereoselective Synthesis of Dinucleotide Boranophosphate, Using Chiral Indole-oxazaphosphorine Intermediates

Yi Jin and George Just*

Department of Chemistry, McGill University, Montreal, Canada H3A 2K6


Received 29 May 1998; accepted 29 June 1998

Abstract: A stereoselective synthesis of a Sp dinucleotide boranophosphate with a de of > 98%, using (S)-3-hydroxy-4-(2-indolyl)butyronitrile as chiral auxiliary, is reported. The conversion of phosphite triester to boranophosphate with $\text{BH}_3\text{-Me}_2\text{S}$ proceeds with retention of configuration at the phosphorus atom. The procedure may be adaptable to solid phase synthesis.

© 1998 Elsevier Science Ltd. All rights reserved.


In the preceding article,¹ we reported the synthesis of the Sp and Rp diastereomers of dithymidine boranophosphate. It has also been known that using chiral auxiliary **1** can lead to stereoselective synthesis of chiral phosphorothioate (de > 97%).² We therefore investigated the use of chiral auxiliary **1** in the synthesis of chiral boranophosphates.

SCHEME 1



As reported,² the chiral auxiliary 1-(S) can be synthesized from (R)-glycidol in 5 steps. In THF, the reaction of 1-(S) with PCl_3 was complete in several minutes to give phosphorochloridite **2** at 0 °C; 5'-O-TBDMS-thymidine (T_3OH) was then added at 0 °C to provide the indole-oxazaphosphorine **3a** consisting of two diastereomers in a ratio of 8 : 1 - 12 : 1. When 3 eq. of **3a** was treated with 1 eq. of 3'-O-TBDPS-thymidine (T_5OH), only one isomer **4a** (^{31}P NMR showed a single peak at 141.61 ppm) was obtained. After reaction with dimethyl sulfide - borane ($\text{BH}_3\text{-Me}_2\text{S}$) (Scheme 1), the phosphite peak disappeared within 5 - 10 min to give a broad peak at 116.83 ppm for boranophosphate **5a**. The diastereomeric ratio could not be determined from ^{31}P NMR spectrum because of peak broadening. We therefore tried to get unprotected dinucleoside boranophosphate **8**. The chiral auxiliary was easily removed with 28% $\text{NH}_3\text{-H}_2\text{O}$ at 50 °C overnight to form **6** (^{31}P NMR 96.53 ppm, broad). The deprotection of the silyl groups on **6** with TBAF or TBAF/HOAc/THF provided the boranophosphate **8** (^{31}P NMR ~93 ppm, broad) in low yield and another product showed a single peak at ~29 ppm in the ^{31}P NMR spectrum. The by-product has no BH_3 moiety since no peak was observed in the ^{11}B NMR spectrum (Scheme 2).

SCHEME 2



In order to improve the yield of dinucleoside boranophosphate **8** and avoid the loss of the BH_3 moiety which was probably due to reaction with fluoride ion, we repeated the reaction of phosphorochloridite **2** with 5'-O-dimethoxytritylated T_3OH . The indole-oxazaphosphorine **3b** was obtained in a diastereomeric ratio of 16 : 1. After adding 3'-O-dimethoxytritylated T_5OH , phosphite triester **4b** was obtained. The reaction of **4b** with $\text{BH}_3\text{-Me}_2\text{S}$ in 2.0 M THF gave boranophosphate **5b** (^{31}P NMR: 117.06 ppm, broad). Interestingly, the DMTr groups on **5b** were not removed in the boronation step even though the reaction was allowed to proceed overnight at RT.¹ Reaction with 70% HOAc removed the DMTr groups and gave **7**, which was

converted to final compound **8** by using 28% $\text{NH}_3\text{-H}_2\text{O}$ in methanol at RT for 1 h. In the coupling step, when 1 eq. of **3b** and 1 eq. of **T₅OH** was used, 10 : 1 of two diastereomers of phosphite triester **4b** (^{31}P NMR: 140.95 : 140.86 ppm = 10 : 1) was obtained. After removing chiral auxiliary, boranophosphates Sp-**8** and Rp-**8** was obtained in the same diastereomeric ratio of 10 : 1 as for **4b**. When 3 eq. of **3b** and 1 eq. of **T₅OH** were used, the coupling reaction provided only one diastereomer of phosphite triester **4b** (^{31}P NMR: 140.96 ppm) which was transformed to only one diastereomer of Sp-**8**. The diastereomeric ratio of **8** could not be obtained from ^{31}P NMR spectrum because of a broad peak at ~ 93 ppm. However, it can be obtained from ^1H NMR with comparison with the data in the literature^{1,3} (Figure 1). Also, the absolute configuration at phosphorus in Sp-**8** and Rp-**8** was assigned by ^1H NMR comparison with literature data.^{1,3}




Figure 1: Part of ^1H NMR Spectra of Sp-**8** (a), Rp-**8** (b)¹ and a diastereomer mixture of Sp-**8** and Rp-**8** (10 : 1) (c) in D_2O . Left spectra: assigned to $^5\text{H-6}$ and $^3\text{H-6}$, Right spectra: assigned to $^5\text{H-1'}$ and $^3\text{H-1'}$.

It is known that the Rp - dithymidine phosphorothioate can be synthesized from chiral auxiliary **1-(S)**² and that the conversion of phosphite triester to phosphorothioate proceeds with retention of stereochemistry.⁴ Since Sp dithymidine boranophosphate was obtained from **1-(S)**, it was concluded that the conversion of phosphite triester to boranophosphate by dimethyl sulfide - borane took place with retention of configuration. Noting that sulfur is the largest atom around the phosphorus center in a nucleotide phosphorothioate while boron is the smallest atom around the phosphorus center in a nucleotide boranophosphate, a Rp configuration in phosphorothioate corresponds to an Sp configuration in boranophosphate.

It should be possible to get pure Rp dithymidine boranophosphate from chiral auxiliary **1-(R)**, since the Sp dithymidine phosphorothioate can be obtained from chiral auxiliary **1-(R)**.² The method reported here might be adaptable to the solid phase synthesis of chiral oligonucleotide boranophosphates.

ACKNOWLEDGMENTS

We wish to thank the Natural Science and Engineering Research Council of Canada and ISIS Pharmaceuticals, Carlsbad, CA, for generous financial support, and Dr. Orval Mamer and Dr. Daniel Boismenu, McGill University Biomedical Mass Spectrometry Unit, for the measurement of mass spectra. Y. J. thanks McGill University for Alexander McFee Memorial fellowship, FCAR Fellowship, J. W. McConnell McGill Major Fellowship and Beijing Memorial McGill Fellowship.

REFERENCES AND NOTES

1. Jin, Y.; Just, G. preceding paper.
2. Wang, J.-C.; Just, G. *Tetrahedron Lett.* **1997**, *38*, 3797 - 3800.
3. Li, H.; Huang, F.; Shaw, B. R. *Bioorganic & Medicinal Chemistry* **1997**, *5*, 787 - 795.
4. (a) Fuji, M.; Ozaki, K.; Sekine, M.; Hata, T. *Tetrahedron* **1987**, *43*, 3395 - 3407; (b) Mikołajczyk, M. *J. Chem. Soc., Chem. Commun.* **1969**, 1221.